L'intérêt à découvert pour QuidelOrtho donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de QuidelOrtho. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

QuidelOrtho (NASDAQ:QDEL) Stock, Rapport sur les intérêts à découvert

QuidelOrtho

QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if the revenue from North America.

Quidel

QuidelOrtho Corp

On Tuesday, QuidelOrtho Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>)&nbsp;priced the previously announced underwritten secondary offering by Carlyle Partners VI Cayman Holdings of <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42079373/quidelortho-corporation-announces-pricing-of-secondary-offering-of-common-stock-by-the-carlyle-gro" rel="noreferrer noopener">8.26 million shares</a>.
The selling stockholder will receive all of the proceeds. The company is not <a href="https://www.benzinga.com/pressreleases/24/11/b42076127/quidelortho-corporation-announces-secondary-offering-of-common-stock-by-the-carlyle-group" target="_blank" rel="noreferrer noopener">selling any shares</a>.
The last reported sale price of QuidelOrtho&#8217;s common stock on Nov. 19 was $38.58 per share. Goldman Sachs &amp; Co. LLC is acting as the sole underwriter.
William Blair analysts noted that Carlyle sold some of its shares earlier this summer through smaller transactions. At that time, investors had suggested block trades or secondary transactions for any further sales by Carlyle. Tuesday&#8217;s announcement aligns with these preferences, which investors may view positively.
While some might interpret this move as a lack of confidence in QuidelOrtho's ongoing improvements, the analysts do not share that view.
Instead, they emphasize considering factors like Carlyle's long ownership period, as the firm originally acquired Ortho Clinical in 2014.
William Blair analysts write, &#8220;We take this as a long-term net-positive for the stock as it removes one of the overhangs that came up in investor conversations around the name.&#8221;
William Blair reiterates a Market Perform rating.
Price Action: QDEL stock is down 4.2% at $36.96 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42092417/salesforce-launches-tools-to-simplify-ai-agent-testing-and-deployment" target="_blank" rel="noreferrer noopener">Salesforce Tool Aims To Simplify AI Agent Testing, Deployment</a></li>
</ul>
Photo: Shutterstock

Analyst Color

News

Health Care

Analyst Ratings

Movers

Trading Ideas

General

QDEL

Carlyle Sells QuidelOrtho Shares, Analyst Sees Overhang Lifted

U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Wednesday.
Shares of Powell Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWL#NASDAQ">POWL</a>) fell sharply in today's pre-market trading after the company <a href="https://www.benzinga.com/quote/POWL/earnings">reported worse-than-expected fourth-quarter revenue results.</a>
Powell Industries reported quarterly earnings of $3.77 per share which beat the analyst consensus estimate of $3.55 per share. The company reported quarterly sales of $275.06 million which missed the analyst consensus estimate of $286.49 million.
Powell Industries shares dipped 15.4% to $264.00 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Target Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) shares declined 16.3% to $129.62 in pre-market trading following downbeat quarterly results.</li>
<li>Destiny Tech100 Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXYZ#NASDAQ">DXYZ</a>) shares dipped 13.4% to $39.18 in pre-market trading after jumping 24% on Tuesday.</li>
<li>Silvercorp Metals Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SVM#NYSE">SVM</a>) fell 11.3% to $3.59 in pre-market trading after the company announced a $130 million convertible senior notes offering.</li>
<li>QuidelOrtho Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) fell 6.7% to $36.01 in today's pre-market trading after the company announced the pricing of secondary offering of common stock by the Carlyle Group.</li>
<li>The First of Long Island Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLIC#NASDAQ">FLIC</a>) fell 5.4% to $13.13 in pre-market trading.</li>
<li>Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) fell 4.8% to $236.90 in pre-market trading.</li>
<li>XP Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XP#NASDAQ">XP</a>) fell 4.1% to $16.00 in pre-market trading following weak quarterly earnings.</li>
<li>Dianthus Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNTH#NASDAQ">DNTH</a>) fell 2.3% to $21.77 in pre-market trading after declining more than 5% on Tuesday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/24/11/42069785/wall-streets-most-accurate-analysts-weigh-in-on-3-defensive-stocks-with-over-5-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Defensive Stocks With Over 5% Dividend Yields</a></li>
</ul>

Pre-Market Outlook

Markets

DNTH

DXYZ

FLIC

POWL

Powell Industries Reports Weak Sales, Joins Target, QuidelOrtho And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Shares of Keysight Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEYS#NYSE">KEYS</a>) rose sharply in today's pre-market trading reported <a href="https://www.benzinga.com/news/earnings/24/11/42075636/keysight-technologies-stock-jumps-on-q4-earnings-revenue-beat-eps-beat-confidence-in-our-ability-to-outperform">better-than-expected earnings for its fourth quarter.</a>
Keysight reported quarterly earnings of $1.65 per share which beat the analyst consensus estimate of $1.57. The company reported quarterly sales of $1.287 billion which beat the analyst consensus estimate of $1.258 billion.
The company said it sees first-quarter revenue of $1.265 billion to $1.285 billion and adjusted earnings of $1.65 to $1.71 per share.
Keysight shares jumped 9.3% to $166.20 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) gained 63.6% to $0.2663 in pre-market trading after jumping 22% on Tuesday.</li>
<li>Nauticus Robotics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KITT#NASDAQ">KITT</a>) rose 59.3% to $1.45 in pre-market trading after the company entered into strategic collaboration with SeaTrepid to integrate and test its ToolKITT software on remotely operated vehicles.</li>
<li>Tevogen Bio Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) gained 41.2% to $1.92 in pre-market trading following third-quarter results.</li>
<li>Digital Brands Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBGI#NASDAQ">DBGI</a>) gained 30.7% to $0.1524 in pre-market trading after jumping around 18% on Tuesday.</li>
<li>JX Luxventure Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JXJT#NASDAQ">JXJT</a>) gained 26.2% to $1.64 in pre-market trading after declining around 12% on Tuesday.</li>
<li>KORE Group Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KORE#NYSE">KORE</a>) gained 25.1% to $2.29 in pre-market trading after the company reported better-than-expected quarterly sales results.</li>
<li>Algorhythm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIME#NASDAQ">RIME</a>) gained 23.4% to $0.3150 in pre-market trading after reporting third-quarter results.</li>
<li>Hoth Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOTH#NASDAQ">HOTH</a>) climbed 22.2% to $0.9993 in pre-market trading after the company was granted U.S. Patent No. 12,144,815 titled &#8220;Use of Aprepitant for Treating Alzheimer&#8217;s Disease.&#8221;</li>
<li>Kingsoft Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) gained 20.8% to $5.55 in pre-market trading. Kingsoft Cloud, on Tuesday, reported a fiscal third-quarter 2024 revenue of 1.89 billion Chinese yuan ($268.7 million), up by 16.0% year-on-year, beating the analyst consensus estimate of $247.46 million.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>PainReform Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRFX#NASDAQ">PRFX</a>) shares tumbled 26.4% to $1.03 in pre-market trading after jumping 162% on Tuesday. The company announced a 1-for-4 reverse stock split.</li>
<li>X3 Holdings Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTKG#NASDAQ">XTKG</a>) fell 27.4% to $0.1050 in pre-market trading. XTKG announced a 1-for-20 share consolidation.</li>
<li>Solidion Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STI#NASDAQ">STI</a>) shares fell 21.2% to $0.5003 in pre-market trading following third-quarter results.</li>
<li>Volato Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOAR#NYSE">SOAR</a>) declined 16.7% to $0.3912 in pre-market trading after jumping 123% on Tuesday. Volato Group, on Monday, reported a year-over-year increase in third-quarter financial results.</li>
<li>HCW Biologics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) shares fell 16.6% to $0.9180 in pre-market trading after dipping 11% on Tuesday. The company announced a $6.9 million direct offering and private placement.</li>
<li>Powell Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWL#NASDAQ">POWL</a>) dipped 15.4% to $264.00 in pre-market trading after the company reported worse-than-expected fourth-quarter revenue results.</li>
<li>Destiny Tech100 Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXYZ#NASDAQ">DXYZ</a>) shares dipped 13.4% to $39.18 in pre-market trading after jumping 24% on Tuesday.</li>
<li>Workhorse Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKHS#NASDAQ">WKHS</a>) fell 13.1% to $1.06 in pre-market trading after posting quarterly results.</li>
<li>Silvercorp Metals Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SVM#NYSE">SVM</a>) fell 11.3% to $3.59 in pre-market trading after the company announced a $130 million convertible senior notes offering.</li>
<li>QuidelOrtho Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) fell 6.7% to $36.01 in today's pre-market trading after the company announced the pricing of secondary offering of common stock by the Carlyle Group.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/24/11/42069785/wall-streets-most-accurate-analysts-weigh-in-on-3-defensive-stocks-with-over-5-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Defensive Stocks With Over 5% Dividend Yields</a></li>
</ul>

DBGI

HCWB

HOTH

JXJT

KEYS

KITT

KORE

PRFX

RIME

SOAR

TNXP

TVGN

WKHS

XTKG

Why Keysight Technologies Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket

Reported Earlier, QuidelOrtho Prices Secondary Offering Of 8.26M Shares By Carlyle Group

Offerings

QuidelOrtho Corporation Announces Secondary Offering Of  8,260,183 Shares By Carlyle Group

As of Nov. 11, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Airsculpt Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRS#NASDAQ">AIRS</a>)</h3>
<ul>
<li>On Nov. 8, AirSculpt Technologies posted better-than-expected quarterly results. &#8220;Our revenue and Adjusted EBITDA for the quarter were in line with our expectations with the period including progress on our strategy despite continued challenges in the consumer environment,&#8221; said Dennis Dean, Interim Chief Executive Officer and Chief Financial Officer of AirSculpt Technologies, Inc. The company's stock gained around 42% over the past five days and has a <a href="https://www.benzinga.com/quote/AIRS">52-week high of $8.88</a>.</li>
<li>RSI Value: 81.89&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>AIRS Price Action: Shares of Airsculpt Technologies gained 20.7% to close at $8.68 on Friday.</li>
</ul>
<h3 class="wp-block-heading">Quidelortho Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>)</h3>
<ul>
<li>On Nov. 7, QuidelOrtho reported better-than-expected third-quarter financial results and issued FY24 revenue above estimates. &#8220;We delivered solid third quarter results, giving us confidence that our strategic priorities and focus on our customers, business growth and margin improvement are gaining traction,&#8221; said Brian J. Blaser, President and Chief Executive Officer, QuidelOrtho. The company's stock gained around 11% over the past five days and <a href="https://www.benzinga.com/quote/QDEL">has a 52-week high</a> of $75.86.</li>
<li>RSI Value: 74.63</li>
<li>QDEL Price Action: Shares of Quidelortho gained 12.6% to close at $43.75 on Friday.</li>
</ul>
<h3 class="wp-block-heading">Nuvation Bio Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUVB#NYSE">NUVB</a>)</h3>
<ul>
<li>On Nov. 6, Nuvation Bio reported financial results for the third quarter ended Sept, 30, and provided a business update. David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio stated: &#8220;In the third quarter, we continued to execute on our goal of bringing taletrectinib to people living with ROS1-positive NSCLC as quickly as possible, which has been our focus since we closed the acquisition of AnHeart Therapeutics earlier this year. In October, we completed the rolling submission of our NDA for line agnostic full approval of taletrectinib in advanced ROS1-positive NSCLC, which was supported by the pooled data from the pivotal Phase 2 TRUST-I and TRUST-II studies that we presented at ESMO. We believe that these data – a confirmed objective response rate of 89% and median duration of response approaching four years in the TKI-naïve setting – are the strongest data seen to date in the ROS1 space and increase taletrectinib&#8217;s potential to become a best-in-class treatment option.&#8221; The company's stock gained around 25% over the past five days and has a <a href="https://www.benzinga.com/quote/NUVB">52-week high</a> of $4.16.</li>
<li>RSI Value: 71.61</li>
<li>NUVB Price Action: Shares of Nuvation Bio gained 9.9% to close at $2.88 on Friday.</li>
</ul>
<h3 class="wp-block-heading">Insulet Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>)</h3>
<ul>
<li>On Nov. 7, Insulet reported better-than-expected third-quarter financial results. &#8220;We continue to achieve significant milestones and robust revenue growth,&#8221; said Jim Hollingshead, President and Chief Executive Officer. The company's stock jumped around 14% over the past five days and has a 52-week high is $275.52.</li>
<li>RSI Value: 87.19</li>
<li>PODD Price Action: Shares of Insulet gained 9.4% to close at $268.00 on Friday. </li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41871463/dow-sp-500-notch-best-week-of-year-as-tesla-surges-post-trump-win-investor-sentiment-improves-fear-greed-index-remains-in-neutral-zone">Dow, S&amp;P 500 Notch Best Week Of Year As Tesla Surges Post Trump Win: Investor Sentiment Improves, Fear &amp; Greed Index Remains In &#8216;Neutral&#8217; Zone</a></li>
</ul>

Short Ideas

AIRS

NUVB

PODD

Top 4 Health Care Stocks That May Plunge This Quarter

Management

QuidelOrtho Determined To Terminate Employment Of Michael S. Iskra, Co's Executive VP And Chief Commercial Officer And Robert J. Bujarski, Co's EVP And Chief Operating Officer

WIIM

QuidelOrtho shares are trading higher after the company reported better-than-expected Q3 financial results and issued FY24 revenue above estimates.

Guidance

QuidelOrtho Sees FY24 Revenue $2.75B-$2.80B Vs $2.713B Est; Sees Adj EPS $1.69-$1.91 Vs $1.73 Est.

QuidelOrtho (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) reported quarterly earnings of $0.85 per share which beat the analyst consensus estimate of $0.32 by 165.63 percent. The company reported quarterly sales of $727.10 million which beat the analyst consensus estimate of $642.10 million by 13.24 percent. This is a 2.27 percent decrease over sales of $744.00 million the same period last year.

Earnings

Earnings Beats

QuidelOrtho Q3 2024 Adj EPS $0.85 Beats $0.32 Estimate, Sales $727.10M Beat $642.10M Estimate

Ratings for QuidelOrtho (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for QuidelOrtho, revealing an average target of $57.25, a high estimate of $61.00, and a low estimate of $50.00. Surpassing the previous average price target of $51.00, the current average has increased by 12.25%.
<img src="https://www.benzinga.com/files/images/story/2024/1726779707_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of QuidelOrtho among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Sourbeer</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$50.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Alexander Nowak</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$57.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$61.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$61.00</td>
<td>$61.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to QuidelOrtho. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of QuidelOrtho compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of QuidelOrtho's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/QDEL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on QuidelOrtho analyst ratings.</a>
<h2>Unveiling the Story Behind QuidelOrtho</h2>
QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if the revenue from North America.
<h3>QuidelOrtho's Financial Performance</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining QuidelOrtho's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately -4.22% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: QuidelOrtho's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -23.19%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): QuidelOrtho's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -4.56%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): QuidelOrtho's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -2.21%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.87.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cracking The Code: Understanding Analyst Reviews For QuidelOrtho

UBS analyst John Sourbeer upgrades QuidelOrtho (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) from Sell to Neutral and raises the price target from $42 to $50.

Upgrades

Price Target

UBS Upgrades QuidelOrtho to Neutral, Raises Price Target to $50

U.S. stocks were mostly lower, with the Dow Jones index falling around 300 points on Thursday.
Shares of G-III Apparel Group, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIII#NASDAQ">GIII</a>) rose sharply during Thursday's session after the company reported better-than-expected second-quarter adjusted EPS results and issued its FY25 guidance above estimates.
G-III Apparel Group reported second-quarter adjusted earnings per share of 52 cents, beating the analyst consensus of 27 cents. Quarterly revenues of $644.75 million (down 2%) missed the street view of $649.44 million.
G-III Apparel Group shares surged 23.6% to $30.95 on Thursday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) shares jumped 68.1% to $5.45 after the company entered agreements for a $160 million private placement financing priced at market, from a group of institutional and accredited investors including NVIDIA and Related Companies.</li>
<li>EchoStar Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SATS#NASDAQ">SATS</a>) gained 14.9% to $21.15.</li>
<li>Larimar Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRMR#NASDAQ">LRMR</a>) climbed 13.5% to $8.81.</li>
<li>Uniti Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNIT#NASDAQ">UNIT</a>) rose 13.3% to $5.32.</li>
<li>Yext, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YEXT#NYSE">YEXT</a>) climbed 13% to $5.56 after the company reported better-than-expected second-quarter adjusted EPS results and issued FY25 revenue guidance above estimates. Also, Needham upgraded the stock from Hold to Buy and announced an $8 price target.</li>
<li>Perpetua Resources Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPTA#NASDAQ">PPTA</a>) rose 11.8% to $9.05 after the company announced the U.S. forest service has completed the final environmental impact statement and issued a draft record of decision authorizing the Stibnite gold project.</li>
<li>Vestis Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSTS#NYSE">VSTS</a>) gained 11.7% to $15.28 following a report suggesting Elis SA made an offer to buy the company.</li>
<li>WK Kellogg Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLG#NYSE">KLG</a>) climbed 10.7% to $18.63.</li>
<li>NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) gained 10.4% to $4.6850 after the company reported second-quarter financial results and issued better-than-expected third-quarter outlook..</li>
<li>Shoe Carnival, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCVL#NASDAQ">SCVL</a>) rose 10% to $41.32 after the company reported better-than-expected second-quarter revenue results. Also, the company raised its FY24 guidance.</li>
<li>Primo Water Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRMW#NASDAQ">PRMW</a>) gained 9.4% to $23.92.</li>
<li>QuidelOrtho Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) gained 8.5% to $43.79. Craig-Hallum analyst Alexander Nowak upgraded QuidelOrtho from Hold to Buy and raised the price target from $40 to $57.</li>
<li>Polestar Automotive Holding UK PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNY#NASDAQ">PSNY</a>) gained 8.3% to $1.3095.</li>
<li>Myriad Genetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) gained 7.9% to $27.36.</li>
<li>Zeta Global Holdings Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) gained 7.8% to $26.83. Zeta Global priced $204.9 million public offering of 13.2 million class A common shares at $23.50 per share.</li>
<li>Sotera Health Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHC#NASDAQ">SHC</a>) gained 7.7% to $16.59. The company announced a secondary offering of 25 million shares.</li>
<li>Dollar Tree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) rose 6.2% to $67.52. Dollar Tree, on Wednesday, reported worse-than-expected second-quarter 2024 earnings.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/09/40728954/how-to-earn-500-a-month-from-smith-wesson-brands-stock-ahead-of-q1-earnings-report">How To Earn $500 A Month From Smith &amp; Wesson Brands Stock Ahead Of Q1 Earnings Report</a></li>
</ul>

Intraday Update

APLD

DLTR

GIII

Larimar Therapeutics, Inc. - Common Stock

LRMR

MYGN

PPTA

PRMW

PSNY

SATS

SCVL

UNIT

VSTS

YEXT

ZETA

G-III Apparel Posts Upbeat Results, Joins NIO, Yext, Shoe Carnival And Other Big Stocks Moving Higher On Thursday

QuidelOrtho shares are trading higher after Craig-Hallum upgraded the stock from Hold to Buy and raised its price target from $40 to $57.

Craig-Hallum analyst Alexander Nowak upgrades QuidelOrtho (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) from Hold to Buy and raises the price target from $40 to $57.

Craig-Hallum Upgrades QuidelOrtho to Buy, Raises Price Target to $57

&nbsp;The presence of antibodies to TP-specific antigens, in conjunction with non-treponemal laboratory tests and clinical findings may aid in the diagnosis of syphilis infection. The VITROS syphilis assay is not intended for blood and tissue donor screening. With the addition of the U.S., the VITROS syphilis assay is now available globally where QuidelOrtho products are available.&nbsp;

QuidelOrtho Has Received FDA 510(k) Clearance For Its Vitros Syphilis Assay. Using The Automated Vitros Systems, This Assay Is Intended For The Qualitative Determination Of Total (IgG and IgM) Antibodies To Treponema Pallidum-specific Antigens In Human Serum And Plasma

RBC Capital analyst Conor McNamara reiterates QuidelOrtho (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) with a Outperform and maintains $61 price target.

Reiteration

RBC Capital Reiterates Outperform on QuidelOrtho, Maintains $61 Price Target

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$35.00</td>
<td>$127.1K</td>
<td>48.0K</td>
<td>3.3K</td>
</tr>
<tr>
<td>NTRA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$105.00</td>
<td>$36.6K</td>
<td>113</td>
<td>1.7K</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$450.00</td>
<td>$30.7K</td>
<td>575</td>
<td>519</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$57.50</td>
<td>$28.0K</td>
<td>3.2K</td>
<td>322</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>08/16/24</td>
<td>$85.00</td>
<td>$29.7K</td>
<td>945</td>
<td>153</td>
</tr>
<tr>
<td>QDEL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$60.00</td>
<td>$29.0K</td>
<td>0</td>
<td>146</td>
</tr>
<tr>
<td>HROW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$12.00</td>
<td>$66.0K</td>
<td>339</td>
<td>100</td>
</tr>
<tr>
<td>BPMC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$95.00</td>
<td>$30.6K</td>
<td>1</td>
<td>80</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$900.00</td>
<td>$76.0K</td>
<td>308</td>
<td>61</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$120.00</td>
<td>$75.1K</td>
<td>83</td>
<td>55</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we observe a call option trade with bullish sentiment. It expires in 162 day(s) on January 17, 2025. Parties traded 3100 contract(s) at a $35.00 strike. The total cost received by the writing party (or parties) was $127.1K, with a price of $41.0 per contract. There were 48092 open contracts at this strike prior to today, and today 3303 contract(s) were bought and sold. 
• For NTRA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), we notice a call option sweep that happens to be bearish, expiring in 8 day(s) on August 16, 2024. This event was a transfer of 39 contract(s) at a $105.00 strike. This particular call needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $36.6K, with a price of $940.0 per contract. There were 113 open contracts at this strike prior to today, and today 1738 contract(s) were bought and sold. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a put option sweep that happens to be bullish, expiring in 134 day(s) on December 20, 2024. This event was a transfer of 58 contract(s) at a $450.00 strike. This particular put needed to be split into 20 different trades to become filled. The total cost received by the writing party (or parties) was $30.7K, with a price of $530.0 per contract. There were 575 open contracts at this strike prior to today, and today 519 contract(s) were bought and sold. 
• Regarding CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we observe a call option trade with bearish sentiment. It expires in 43 day(s) on September 20, 2024. Parties traded 100 contract(s) at a $57.50 strike. The total cost received by the writing party (or parties) was $28.0K, with a price of $280.0 per contract. There were 3203 open contracts at this strike prior to today, and today 322 contract(s) were bought and sold. 
• Regarding MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we observe a put option sweep with neutral sentiment. It expires in 8 day(s) on August 16, 2024. Parties traded 100 contract(s) at a $85.00 strike. This particular put needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $29.7K, with a price of $298.0 per contract. There were 945 open contracts at this strike prior to today, and today 153 contract(s) were bought and sold. 
• For QDEL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>), we notice a call option sweep that happens to be bullish, expiring in 225 day(s) on March 21, 2025. This event was a transfer of 121 contract(s) at a $60.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $29.0K, with a price of $240.0 per contract. There were 0 open contracts at this strike prior to today, and today 146 contract(s) were bought and sold. 
• For HROW (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>), we notice a call option trade that happens to be bearish, expiring in 71 day(s) on October 18, 2024. This event was a transfer of 30 contract(s) at a $12.00 strike. The total cost received by the writing party (or parties) was $66.0K, with a price of $2200.0 per contract. There were 339 open contracts at this strike prior to today, and today 100 contract(s) were bought and sold. 
• For BPMC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>), we notice a call option trade that happens to be bearish, expiring in 162 day(s) on January 17, 2025. This event was a transfer of 30 contract(s) at a $95.00 strike. The total cost received by the writing party (or parties) was $30.6K, with a price of $1020.0 per contract. There were 1 open contracts at this strike prior to today, and today 80 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a call option trade that happens to be bullish, expiring in 99 day(s) on November 15, 2024. This event was a transfer of 20 contract(s) at a $900.00 strike. The total cost received by the writing party (or parties) was $76.0K, with a price of $3800.0 per contract. There were 308 open contracts at this strike prior to today, and today 61 contract(s) were bought and sold. 
• Regarding DHR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>), we observe a call option sweep with bearish sentiment. It expires in 134 day(s) on December 20, 2024. Parties traded 5 contract(s) at a $120.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $75.1K, with a price of $15020.0 per contract. There were 83 open contracts at this strike prior to today, and today 55 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

BPMC

HROW

MRNA

NTRA

10 Health Care Stocks Whale Activity In Today's Session

QuidelOrtho shares are trading higher after the company reported better-than-expected Q2 financial results.

In a report released today, Conor McNamara from RBC Capital maintained a Buy rating on QuidelOrtho (QDEL – Research Report), with a price target of...

RBC Capital Sticks to Its Buy Rating for QuidelOrtho (QDEL)

QuidelOrtho (QDEL) disclosed that in connection with a leadership reorganization, it took the following actions: The company determined to terminat...

QuidelOrtho terminates chief commercial and chief operating officers

QuidelOrtho ( ($QDEL) ) has shared an announcement. QuidelOrtho Corporation is undergoing a leadership shakeup, terminating the roles of two key ex...

QuidelOrtho Announces Leadership Changes, New COO Appointed

Barry Rosenstein's Jana Partners disclosed in an SEC filing its holdings as of September 30, 2024. Jana made a new buy in Q3: $228.3M of Lamb Westo...

Jana adds Lamb Weston during Q3, exits BlackLine

Jana Partners takes new stake in Lamb Weston, exits BlackLine, among top Q3 trades

High quality 'SMID-cap' stocks with cyclical exposure – MS

The company is not offering or selling any shares of common stock under this prospectus and will not receive any proceeds from the sale of the comm...

QuidelOrtho files to sell 8.26M shares of common stock for holders

QuidelOrtho files to sell 8.26M shares of common stocks by selling shareholders

QuidelOrtho (QDEL) announced the launch of an underwritten secondary offering by Carlyle Partners VI Cayman Holdings, L.P. of 8,260,183 shares of t...

QuidelOrtho announces 8.26M share offering of common stock for holders

The deal priced at low end of $35.60-$36.60 range and below last closing price of $38.58. Goldman Sachs is acting as sole book running manager for ...

QuidelOrtho 8.26M share Spot Secondary priced at $35.60

AGIO

AMRX

AROC

ASAN

ASGN

CARG

CEIX

CPRI

DBRG

EHAB

FYBR

GBTG

GLNG

HWKN

IBRX

IOVA

LBRT

MRCY

OSCR

SDRL

SKYW

SPTM

STRL

TBBK

TCBI

TGLS

TGNA

TRMB

UMBF

USLM

WERN

Press Releases

VITROS® Syphilis Assay Now Available on VITROS 3600 Immunodiagnostic System, VITROS 5600 and VITROS XT 7600 Integrated Systems in the U.S.

QuidelOrtho Appoints Lee Bowman as Chief Human Resources Officer

QuidelOrtho Announces New R&D Executive Leader

QuidelOrtho to Report Third Quarter 2024 Financial Results

QuidelOrtho to Participate in Three Upcoming Investor Conferences

Legal

Kuehn Law Encourages Investors of QuidelOrtho Corporation to Contact Law Firm

QuidelOrtho Reports Third Quarter 2024 Financial Results

QuidelOrtho Corporation Announces Secondary Offering of Common Stock by the Carlyle Group

QuidelOrtho Corporation Announces Pricing of Secondary Offering of Common Stock by the Carlyle Group

Comments

QuidelOrtho

Intérêt court

QuidelOrtho (NASDAQ:QDEL) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL